Baseline laboratory panel: difference between revisions
Diff·revision 13 → 14·14:58, 17 Apr 2025
Difference between revision 13 and revision 14 of Baseline laboratory panel. 3 lines changed; the page grew by 487 bytes.
| Revision 13 — 01:54, 30 Mar 2025 Chromatokid (talk) split the analytical performance from the clinical interpretation 3,039 bytes ±0 | Revision 14 — 14:58, 17 Apr 2025 StubSorterBot (talk) bot: update parent category chain 3,526 bytes +487 | ||
|---|---|---|---|
| 32 | Reference intervals are laboratory-specific, derived from that laboratory's own population and assay. A value described as "out of range" is out of that laboratory's range, and a value from another laboratory may sit differently against its own.{{r|wallace2004}} | 32 | Reference intervals are laboratory-specific, derived from that laboratory's own population and assay. A value described as "out of range" is out of that laboratory's range, and a value from another laboratory may sit differently against its own.{{r|wallace2004}} |
| 33 | 33 | ||
| + | 34 | Regression to the mean operates on any value selected for being extreme. A repeat measurement after an abnormal one tends to be closer to the mean whether or not anything was done in between — which is why a single abnormal value is weaker evidence than a trend.{{r|hrobjartsson2010}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |
| 36 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 38 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 37 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). PMID 15161807.</ref> | 39 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). PMID 15161807.</ref> |
| + | 40 | <ref name="hrobjartsson2010">Hróbjartsson A, Gøtzsche PC. "Placebo interventions for all clinical conditions." ''Cochrane Database of Systematic Reviews'' (1):CD003974 (2010). PMID 20091554.</ref> | |
| 38 | 41 | ||
| 39 | == See also == | 42 | == See also == |